Refractory follicular helper T-cell lymphoma, angioimmunoblastic-type

Clinical trials for Refractory follicular helper T-cell lymphoma, angioimmunoblastic-type explained in plain language.

Never miss a new study

Get alerted when new Refractory follicular helper T-cell lymphoma, angioimmunoblastic-type trials appear

Sign up with your email to follow new studies for Refractory follicular helper T-cell lymphoma, angioimmunoblastic-type, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Not yet recruiting 1 Not yet finished but already full! 1

New drug cocktails aim to outsmart Hard-to-Treat T-Cell lymphomas

Disease control Not yet recruiting

This early-phase trial tests two different drug combinations for people with T-cell lymphoma that has come back or not responded to prior treatment. One group receives belinostat plus azacitidine; the other receives belinostat plus pralatrexate. The goal is to find the safest dos…

Matched conditions: REFRACTORY FOLLICULAR HELPER T-CELL LYMPHOMA, ANGIOIMMUNOBLASTIC-TYPE

Phase 1 • Sponsor: City of Hope Medical Center • Aim: Disease control

Last updated Jul 11, 2026 00:00 UTC

Refractory follicular helper T-cell lymphoma, angioimmunoblastic-type

Get alerted when new Refractory follicular helper T-cell lymphoma, angioimmunoblastic-type trials appear

New drug cocktails aim to outsmart Hard-to-Treat T-Cell lymphomas